Abstract
Grapefruit juice elevates blood levels of some drugs taken orally, primarily by inhibiting intestinal CYP3A4-mediated first-pass metabolism. Two prominent furanocoumarins in the juice, 6′,7′-dihydroxybergamottin (DHB) and bergamottin (BG), have been demonstrated as important contributors to grapefruit juice-drug interactions. Using CYP3A4-expressing Caco-2 cells and representative probes from distinct CYP3A4 substrate subgroups (midazolam, testosterone), we compared the time-dependent inhibitory properties of DHB and BG. DHB rapidly inhibited CYP3A4 activity in a substrate-independent fashion with maximal inhibition (≥85%) generally occurring within 30 min. In contrast, BG had a slower onset and exhibited substrate-dependent inhibition. Whereas testosterone 6β-hydroxylation was inhibited by >50% with all exposure times (0.5-3 h), midazolam 1′-hydroxylation was unaffected, or even activated, with short exposure times (<1 h). After a 3-h exposure, however, BG had begun to “catch up” with DHB, causing ≥70% inhibition, independent of substrate. Likewise, loss of CYP3A4 protein, believed to reflect rapid intracellular degradation of the enzyme following mechanism-based inactivation, was comparable between the furanocoumarins (40-50%). The time course of BG-mediated inhibition was similar after just a 30-min exposure, indicating that the short exposure presumed to occur after juice ingestion is sufficient to initiate the events required to cause substantial inhibition (≥50%). These results suggest that after ingestion of a glass of grapefruit juice, CYP3A4 is maximally inhibited by DHB before BG has the opportunity to act. However, foods containing BG but not DHB (e.g., lime juice) could produce a substrate-dependent interaction with drugs consumed concomitantly, but a substrate-independent interaction with drugs taken several hours after food consumption.
Footnotes
-
This work was supported by the National Institutes of Health Grants GM38149 and RR00046.
-
doi:10.1124/jpet.104.076836.
-
ABBREVIATIONS: BG, bergamottin; DHB, 6′,7′-dihydroxybergamottin; 1α,25-(OH)2-D3, 1α,25-dihydroxyvitamin D3; 6β-OH TST, 6β-hydroxytestosterone; 1′-OH MDZ, 1′-hydroxymidazolam; TEMED, N,N,N',N'-tetramethylethylenediamine; HPLC, high-performance liquid chromatography; Papp, apparent permeability coefficient(s); A→ B, apical-to-basolateral; B→ A, basolateral-to-apical; HSA, human serum albumin; DMEM, Dulbecco's modified Eagle's medium; IOD, integrated optical density.
- Received August 28, 2004.
- Accepted October 13, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|